John Schallenkamp is an Oncology physician affiliated with Billings Clinic. OpenAlex indexes 22 publications with 1,299 citations (h-index 11).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
801 N 29th St
Billings, MT 591010905
Telephone
406-238-2500Provider last certified this registry record 15 Jul 2025.
Industry payments
5 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Pinnacle Biologics, IncProgram year20251 payment
- Siemens Medical Solutions USA, Inc.Program year20253 payments
- Novocure Inc.Program year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2014–2025 per NIH RePORTER. The latest:
- Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and Wyoming
Montana Cancer Consortium
FY2025$755,012UG1CA189872 - Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and Wyoming
Montana Cancer Consortium
FY2024$664,153UG1CA189872 - Montana Cancer Consortium: An Inclusive and Collaborative Approach to Clinical Trial Accrual and Cancer Care Delivery Research across Montana, Idaho and Wyoming
Montana Cancer Consortium
FY2023$1,069,045UG1CA189872
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- P2.08.23 Safety and Biomarker Analysis of Nrg-Lu004: Phase I Trial of Radiotherapy With Durvalumab in PD-L1 High LA-NSCLC
Journal of Thoracic Oncology
2025 - SWOG/NCI Phase II Dual Anti–CTLA-4/PD-1 Blockade in Rare Tumors: Nonepithelial Ovarian Cancer
Clinical Cancer Research
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Bradford Whitcomb, MD
Billings Clinic
Eugen Dolan, MD
Billings Clinic
Alexis Hokenstad, MD
Billings Clinic
Mark Piedra, MD
Billings Clinic
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”